

REMARKS

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested. Pursuant to 37 CFR § 1.121, attached as Appendix A is a Version With Markings to Show Changes Made.

In accordance with the Communication and Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated September 30, 2002 (copy enclosed), which was issued in connection with the above-identified application, applicants have enclosed the following:

a computer readable form (CRF) copy of the "Sequence Listing," in the form of a 3.5" diskette;

a paper copy of the "Sequence Listing," as well as the above Amendment directing its entry into the specification; and


a statement that the content of the paper and computer readable form are the same and include no new matter.

With regard to the September 30, 2002, Communication, applicants note that all applicable sequences are identified by their SEQ. ID. Nos. In particular, the sequence identified at page 20, line 4 was identified as SEQ. ID. No. 5 in the Amendment filed on February 28, 2001. Moreover, the sequence found on page 73, line 1 of the specification has been labeled as SEQ. ID. No. 7 and added to the Sequence Listing submitted herewith.

In view of the all of the foregoing, applicants submit that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: October 28, 2002


Georgia Evans
Registration No. 44,597

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603
Telephone: (585) 263-1672
Facsimile: (585) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office P.O. BOX 2327 Arlington, VA 22202, on the date below.	
Date <u>Oct. 28, 2002</u>	<u>Ruth R. Smith</u> Ruth R. Smith

Appendix A
Version With Markings to Show Changes Made

In reference to the amendments made herein to the specification, additions appear as underlined text, while deletions appear as bracketed text, as indicated below.

In the Specification:

At page 73, lines 1-3:

Lou, Q., Leftwich, M. E. & Lam, K. S. (1996) *Identification of GIYWHHY as a Novel Peptide Substrate for Human p60c-src Protein Tyrosine Kinase*. Biorganic & Medicinal Chemistry, **4, 677-682 (SEQ. ID. No. 7).**